Walleye Capital
KNSA icon

Walleye Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Walleye Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$3.88K – 4852
2025
Q3 		$3.88K Buy
+100
New +$3.25K ﹤0.01% 4330

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Walleye Capital's KNSA Position: Q1 2026 in Review

Walleye Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 143,293 shares — an estimated $5.91M sold.

Walleye Capital first reported a position in KNSA in Q4 2021 and held it in 10 quarters. The position peaked at $16M in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Walleye Capital reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 143,293 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $5.91M.
  • Walleye Capital first reported a position in Kiniksa Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • Walleye Capital's Kiniksa Pharmaceuticals position peaked at $16M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.